Der Nervenarzt

, Volume 78, Supplement 1, pp 7–14

Kopfschmerzen und Migräne

CME Weiterbildung • Zertifizierte Fortbildung

Zusammenfassung

Kopfschmerzen gehören zu den am häufigsten beklagten Beschwerden und Symptomen in der ärztlichen Praxis. In den letzten 100 Jahren hat sich ein dramatischer Wissenszuwachs in den Bereichen Epidemiologie, Pathophysiologie, Akuttherapie und präventiver Therapie ergeben. Der Durchbruch in der Akutbehandlung von Migräneattacken kam mit der Einführung der Triptane. Für die medikamentöse Migräneprophylaxe stehen β-Rezeptoren-Blocker, Kalziumantagonisten und Neuromodulatoren zur Verfügung. Unbefriedigend ist immer noch die Behandlung des chronischen Spannungskopfschmerzes. Der Clusterkopfschmerz wird in der Gruppe der trigeminoautonomen Kopfschmerzen subsumiert. Eine zunehmend wichtige Rolle spielt der medikamenteninduzierte Dauerkopfschmerz. Neue Versorgungsstrukturen wie die integrierte Versorgung Kopfschmerz sorgen für eine bessere Betreuung von Patienten mit chronischen Kopfschmerzen.

Schlüsselwörter

Kopfschmerzen Epidemiologie Migräne Spannungskopfschmerz Clusterkopfschmerz Medikamenteninduzierter Dauerkopfschmerz 

Headache and migraine

Summary

Headaches are one of the most common disorders and symptoms in daily medical practice. There has been dramatic progress of knowledge in the fields of epidemiology, pathophysiology, acute treatment, and preventive therapy over the past 100 years. Triptans have been the breakthrough in the treatment of acute migraine attacks. Beta blockers, calcium antagonists, and neuromodulators are available for preventive migraine therapy. Treatment for chronic tension headache is still unsatisfying. Cluster headache is part of the group of trigemino-autonomic headaches. Headache from medication overuse plays an increasingly important role. New medical care structures such as integrated headache care provide better support for patients with chronic headache disorders.

Keywords

Cluster headache Epidemiology Headaches Medication overuse headache Migraine Tension headache 

Literatur

  1. 1.
    Headache Classification Committee of the International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia [Suppl 7] 8: 1–93Google Scholar
  2. 2.
    Olesen J, Bousser M-G, Diener H et al. (2004) The International Classification of Headache Disorders. 2nd edn. Cephalalgia [Suppl 1] 24: 1–160Google Scholar
  3. 3.
    Schwartz BS, Stewart WF, Simon D, Lipton RB (1998) Epidemiology of tension-type headache. JAMA 279: 381–383PubMedCrossRefGoogle Scholar
  4. 4.
    Silberstein SD, Lipton RB (1993) Epidemiology of migraine. Neuroepidemiology 12: 179–194PubMedCrossRefGoogle Scholar
  5. 5.
    Kavuk IYA, Cetindere U, Agelink MW, Diener HC (2003) Epidemiology of chronic daily headache. Eur J Med Res 8: 236–240PubMedGoogle Scholar
  6. 6.
    Lanteri-Minet M, Radat F, Chautard MH, Lucas C (2005) Anxiety and depression associated with migraine: influence on migraine subjects‘ disability and quality of life, and acute migraine management. Pain 118: 319–326PubMedCrossRefGoogle Scholar
  7. 7.
    Radat F, Swendsen J (2005) Psychiatric comorbidity in migraine: a review. Cephalalgia 25: 165–178PubMedCrossRefGoogle Scholar
  8. 8.
    Oedegaard KJ, Neckelmann D, Mykletun A et al. (2006) Migraine with and without aura: association with depression and anxiety disorder in a population-based study. The HUNT Study. Cephalalgia 26: 1–6PubMedCrossRefGoogle Scholar
  9. 9.
    Scher AI, Bigal ME, Lipton RB (2005) Comorbidity of migraine. Curr Opin Neurol 18: 305–310PubMedCrossRefGoogle Scholar
  10. 10.
    Kurth T, Holtmann G, Neufang-Huber J et al. (2006) Prevalence of unexplained upper abdominal symptoms in patients with migraine. Cephalalgia 26: 506–510PubMedCrossRefGoogle Scholar
  11. 11.
    Bigal ME, Lipton RB (2006) Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 67: 252–257PubMedCrossRefGoogle Scholar
  12. 12.
    Diener HC, Kurth T, Dodick D (2007) Patent foramen ovale, stroke, and cardiovascular disease in migraine. Curr Opin Neurol 20: 310–319PubMedCrossRefGoogle Scholar
  13. 13.
    Kurth T, Slomke MA, Kase CS et al. (2005) Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 64: 1020–1026PubMedGoogle Scholar
  14. 14.
    Kurth T, Gaziano JM, Cook NR et al. (2006) Migraine and risk of cardiovascular disease in women. JAMA 296: 283–291PubMedCrossRefGoogle Scholar
  15. 15.
    Kurth T, Gaziano JM, Cook NR et al. (2007) Migraine and risk of cardiovascular disease in men. Arch Intern Med 167: 795–801PubMedCrossRefGoogle Scholar
  16. 16.
    Scher A, Terwindt G, Picavet H et al. (2005) Cardiovascular risk factors and migraine: The GEM population-based study. Neurology 64: 614–620PubMedGoogle Scholar
  17. 17.
    Diener HC, Kurth T, Dodick D (2007) Patent foramen ovale and migraine. Curr Pain Headache Rep 11: 236–240PubMedCrossRefGoogle Scholar
  18. 18.
    Hadjikhani N, Sanchez del Rio M, Wu O et al. (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 98: 4687–4692PubMedCrossRefGoogle Scholar
  19. 19.
    Sanchez del Rio M, Bakker D, Wu O et al. (1999) Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia 19: 701–707CrossRefGoogle Scholar
  20. 20.
    Kirchmann M, Thomsen LL, Olesen J (2006) Basilar-type migraine: clinical, epidemiologic, and genetic features. Neurology 66: 880–886PubMedCrossRefGoogle Scholar
  21. 21.
    Neuhauser HK, Radtke A, Brevern M von et al. (2006) Migrainous vertigo: prevalence and impact on quality of life. Neurology 67: 1028–1033PubMedCrossRefGoogle Scholar
  22. 22.
    Creutzig A, Alexander K (1985) Ergotismus. Dtsch Med Wochenschr 110: 1420–1422PubMedGoogle Scholar
  23. 23.
    Zschiedrich M, Heidrich H, Dienes HP (1985) Ergotismus: Epidemiologie, Pathogenese, Histomorphologie, Diagnostik und Therapie. Med Klinik 80: 721–727Google Scholar
  24. 24.
    Füeßel H (1987) Chronischer Ergotismus. Selecta 33: 20063Google Scholar
  25. 25.
    Humphrey PPA, Feniuk W, Perren M et al. (1989) Sumatriptan succinate. Drugs Future 14: 35–39Google Scholar
  26. 26.
    Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358: 1668–1675PubMedCrossRefGoogle Scholar
  27. 27.
    Fox AW, Chambers CD, Anderson PO et al. (2002) Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache 42: 8–15PubMedCrossRefGoogle Scholar
  28. 28.
    Fiore M, Shields KE, Santanello N, Goldberg MR (2005) Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004. Cephalalgia 25: 685–688PubMedCrossRefGoogle Scholar
  29. 29.
    Diener H, Pfaffenrath V, Pageler L et al. (2005) The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multi-centre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 25: 776–778PubMedCrossRefGoogle Scholar
  30. 30.
    Goldstein J, Silberstein SD, Saper JR et al. (2006) Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache 46: 444–453PubMedCrossRefGoogle Scholar
  31. 31.
    Leinisch E, Evers S, Kaempfe N et al. (2005) Evaluation of the efficacy of intravenous acetaminophen in the treatment of acute migraine attacks: a double-blind, placebo-controlled parallel group multicenter study. Pain 117: 396–400PubMedCrossRefGoogle Scholar
  32. 32.
    Diener H, Limmroth V, Fritsche G et al. (2005) Therapie der Migräneattacke und Migräneprophylaxe. Leitlinie der Deutschen Gesellschaft für Neurologie und der Deutschen Migräne- und Kopfschmerzgesellschaft. In: Diener H, für die Kommission Leitlinien der DGN (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie. 3. Aufl. Thieme, StuttgartGoogle Scholar
  33. 33.
    Bussone G, Diener H, Pfeil J, Schwalen S (2005) Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 59: 961–968PubMedCrossRefGoogle Scholar
  34. 34.
    Silberstein SD, Lipton RB, Dodick DW et al. (2007) Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47: 170–180PubMedCrossRefGoogle Scholar
  35. 35.
    Silvestrini M, Bartolini M, Coccia M et al. (2003) Topiramate in the treatment of chronic migraine. Cephalalgia 23: 820–824PubMedCrossRefGoogle Scholar
  36. 36.
    Diener H, Bussone G, Van Oene J et al. (2007) Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia 27(7): 814–823PubMedCrossRefGoogle Scholar
  37. 37.
    Ayata C, Jin H, Kudo C et al. (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59: 652–661PubMedCrossRefGoogle Scholar
  38. 38.
    Linde K, Streng A, Jurgens S et al. (2005) Acupuncture for patients with migraine: a randomized controlled trial. JAMA 293: 2118–2125PubMedCrossRefGoogle Scholar
  39. 39.
    Diener HC, Kronfeld K, Boewing G et al. (2006) Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial. Lancet Neurol 5: 310–316PubMedCrossRefGoogle Scholar
  40. 40.
    MacGregor EA, Frith A, Ellis J et al. (2006) Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology 67: 2159–2163PubMedCrossRefGoogle Scholar
  41. 41.
    Ashina S, Bendtsen L, Ashina M et al. (2006) Generalized hyperalgesia in patients with chronic tension-type headache. Cephalalgia 26: 940–948PubMedCrossRefGoogle Scholar
  42. 42.
    Russell MB, Saltyte-Benth J, Levi N (2006) Are infrequent episodic, frequent episodic and chronic tension-type headache inherited? A population-based study of 11 199 twin pairs. J Headache Pain 7: 119–126PubMedCrossRefGoogle Scholar
  43. 43.
    Schmidt-Wilcke T, Leinisch E, Straube A et al. (2005) Gray matter decrease in patients with chronic tension type headache. Neurology 65: 1483–1486PubMedCrossRefGoogle Scholar
  44. 44.
    Zissis NP, Harmoussi S, Vlaikidis N et al. (2007) A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. Cephalalgia 27: 315–324PubMedCrossRefGoogle Scholar
  45. 45.
    Lampl C, Marecek S, May A, Bendtsen L (2006) A prospective, open-label, long-term study of the efficacy and tolerability of topiramate in the prophylaxis of chronic tension-type headache. Cephalalgia 26: 1203–1208PubMedCrossRefGoogle Scholar
  46. 46.
    Silberstein SD, Gobel H, Jensen R et al. (2006) Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 26: 790–800PubMedCrossRefGoogle Scholar
  47. 47.
    Mathew NT, Frishberg BM, Gawel M et al. (2005) Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45: 293–307PubMedCrossRefGoogle Scholar
  48. 48.
    Horton BT, Peters GA (1963) Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect: report of 52 cases. Headache 3: 214–226CrossRefGoogle Scholar
  49. 49.
    Peters GA, Horton BT (1951) Headache: with special reference to the excessive use of ergotamine preparations and withdrawal effects. Proceed Staff Meet Mayo Clin 26: 153–161Google Scholar
  50. 50.
    Dichgans J, Diener HC, Gerber WD et al. (1984) Analgetika-induzierter Dauerkopfschmerz. Dtsch Med Wochenschr 109: 369–373PubMedCrossRefGoogle Scholar
  51. 51.
    Diener HC, Limmroth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3: 475–483PubMedCrossRefGoogle Scholar
  52. 52.
    Limmroth V, Katsarava Z, Fritsche G et al. (2002) Features of medication overuse headache following overuse of different acute headache drugs. Neurology 59: 1011–1014PubMedGoogle Scholar
  53. 53.
    Paemeleire K, Bahra A, Evers S et al. (2006) Medication-overuse headache in patients with cluster headache. Neurology 67: 109–113PubMedCrossRefGoogle Scholar
  54. 54.
    Cittadini E, May A, Straube A et al. (2006) Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. Arch Neurol 63: 1537–1542PubMedCrossRefGoogle Scholar
  55. 55.
    Leone M, Franzini A, D’Amico D et al. (2001) Stereotactic electrode implant in inferior posterior hypothalamic gray matter to relieve intractable chronic cluster headache: the first reported case. Neurology [Suppl 3] 56: A218Google Scholar
  56. 56.
    Leone M, Franzini A, Broggi G, Bussone G (2003) Hypothalamic deep brain stimulation for intractable chronic cluster headache: a 3-year follow up. J Neurol Sci [Suppl 2] 24: 143–145Google Scholar
  57. 57.
    Schoenen J, Di Clemente L, Vandenheede M et al. (2005) Hypothalamic stimulation in chronic cluster headache: a pilot study of efficacy and mode of action. Brain 128: 940–947PubMedCrossRefGoogle Scholar
  58. 58.
    Magis D, Allena M, Bolla M et al. (2007) Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study. Lancet Neurol 6: 314–321PubMedCrossRefGoogle Scholar
  59. 59.
    Schwedt TJ, Dodick DW, Hentz J et al. (2007) Occipital nerve stimulation for chronic headache – long-term safety and efficacy. Cephalalgia 27: 153–157PubMedCrossRefGoogle Scholar
  60. 60.
    Burns B, Watkins L, Goadsby PJ (2007) Treatment of medically intractable cluster headache by occipital nerve stimulation: long-term follow-up of eight patients. Lancet 369: 1099–1106PubMedCrossRefGoogle Scholar
  61. 61.
    Chang YJ, Ryu SJ, Lee TH (2006) Dose titration to reduce dipyridamole-related headache. Cerebrovasc Dis 22: 258–262PubMedCrossRefGoogle Scholar
  62. 62.
    Olesen J, Diener H, Husstedt IW et al. (2004) Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. N Engl J Med 350: 1104–1110PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2007

Authors and Affiliations

  1. 1.Universitätsklinik für NeurologieUniversitätsklinikumEssenDeutschland

Personalised recommendations